Seeking Alpha

Merck's sales fall on patent expiries

  • Merck's (MRK) worldwide revenue falls 11% Y/Y as Singulair sales dip 80% from Q2 2012 — the asthma treatment lost patent expiration in the U.S. last August and in Europe in February.
  • Overall, Q2 pharmaceutical sales fall 12% to $9.3B.
  • Revenue growth (including FX impact) from other key products: Januvia, 1%; Zetia, 3%; Remicade, 2%; Junumet, 16%; Vytorin, -6%; Isentress, 4%; Gardasil, 18%; Proquad, M-M-R II, Varivax, 7%; Nasonex, 11%; Consumer Care, -11% (impact of terminating distribution arrangements in China).
  • Outlook: FY $3.45-3.55/ share; revenue -5 to -6% Y/Y. Shares -0.19% premarket. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: